ClinicalTrials.gg
Active, not recruitingNCT03976063TOCOPROMUpdated Apr 23, 2026

Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation

A Phase 3 interventional study of Nifedipine and Placebo of Nifedipine in Preterm Premature Rupture of Membrane, sponsored by Assistance Publique - Hôpitaux de Paris. Active, not recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
857
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.

Read the detailed description

Preterm premature rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-third of preterm births. It is a leading cause of neonatal mortality and morbidity and increases the risk of maternal infectious morbidity. In cases of early PPROM (22 to 33 completed weeks' gestation), expectant management is recommended in the absence of labor, chorioamnionitis or fetal distress. Antenatal steroids and antibiotics administration are recommended by international guidelines. However, there is no recommendation regarding tocolysis administration in the setting of PPROM. In theory, reducing uterine contractility should delay delivery and reduce risks of prematurity and neonatal adverse consequences. Likewise, a prolongation of gestation may allow administering a corticosteroids complete course that is associated with a two-fold reduction of morbidity and mortality. However, tocolysis may prolong fetal exposure to inflammation and be associated with higher risk of materno-fetal infection, potentially associated with neonatal death or long-term sequelae, including cerebral palsy.

The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.

02

Conditions studied

  • Preterm Premature Rupture of Membrane

Keywords

  • Preterm premature rupture of membranes
  • Tocolysis
  • Nifedipine
  • Latency
  • Neonatal outcome
  • Preterm birth
  • Randomized controlled trial
03

In context

Preterm Premature Rupture of the Membranes

76 studies on the registry are indexed under Preterm Premature Rupture of the Membranes; 17 are open to participants now.

This study's enrollment of 857 is above the median of 91 across 50 interventional studies indexed under Preterm Premature Rupture of the Membranes.

Browse Preterm Premature Rupture of the Membranes studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm premature rupture of membranes (PPROM) between 220/7 - 336/7 weeks of gestation, as diagnosed by obstetric team
  • Singleton gestation
  • Fetus alive at the time of randomization (reassuring fetal heart monitoring)
  • 18 years of age or older
  • French speaking
  • Affiliated to social security regime or an equivalent system
  • and signed

Exclusion criteria

Exclusion Criteria:

  • PPROM ≥ 24 hours before diagnosis
  • Ongoing tocolytic treatment at the time of PPROM
  • Tocolytic treatment with Nifedipine between PPROM diagnosis and randomization
  • Fetal condition contraindicating expectant management including chorioamnionitis, placental abruption, intrauterine fetal demise, non-reassuring fetal heart rate at the time of randomization
  • Cervical dilation > 5 cm
  • Iatrogenic rupture caused by amniocentesis or trophoblast
  • Major fetal anomaly
  • Maternal allergy or to Nifedipine or placebo drug components*:

    • Myocardial infarction
    • Unstable angina pectoris
    • Hepatic insufficiency
    • Cardiovascular shock
    • Beta blockers

placebo drug components: lactose monohydrate, colloidal silica, microcrystalline cellulose

  • Coadministration of diltiazem or rifampicin
  • Hypotension (systolic pressure \< 90 mmHg)
  • Participation to another interventional research (category 1) in which intervention could interfere with TOCOPROM's results (efficacy and safety)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
857 participants (actual)

Study arms

  • Active comparator
    Nifedipine

    Drug: Nifedipine

  • Placebo comparator
    Placebo

    Drug: Placebo of Nifedipine

Interventions

  • Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)

  • DrugPlacebo of Nifedipine

    Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43

06

What researchers measure

Primary outcomes

  1. Perinatal morti-morbidity

    Composite outcome including fetal death, neonatal death and/or neonatal severe morbidity (mechanical ventilation ≥ 48 hrs, severe bronchopulmonary dysplasia, severe intraventricular hemorrhage, cystic periventricular leucomalacia, neonatal early-onset sepsis, necrotizing enterocolitis, retinopathy of prematurity).

    Time frame: Up to discharge from hospital, with a maximum of 24 weeks after birth.

Secondary outcomes

  1. Prolongation of gestation

    Latency duration (defined as the duration from PPROM to delivery)

    Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)

  2. Prolongation of gestation

    Pregnancy prolongation beyond 48 hours after randomization

    Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)

  3. Prolongation of gestation

    Pregnancy prolongation beyond 1 week after randomization

    Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)

  4. Prolongation of gestation

    Gestational age at delivery

    Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)

  5. Prolongation of gestation

    Delivery after 37 weeks of gestation

    Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)

  6. Maternal morbidity

    Endometritis, based on clinical diagnosis associating fever (temperature ≥ 38.0°C) with uterine tenderness, purulent or foul-smelling lochia, and in the absence of any other cause.

    Time frame: During the first 10 days postpartum

  7. Maternal morbidity

    Intra-uterine infection, defined as fever (maternal temperature ≥38 °C), with no alternative cause identified, associated with at least two of the following criteria: persistent fetal tachycardia \> 160 bpm, uterine pain or painful uterine contractions or spontaneous labor, purulent amniotic fluid.

    Time frame: At delivery

  8. Fetal mortality

    Fetal death

    Time frame: Up to delivery so up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)

  9. Neonatal mortality

    Neonatal death

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  10. Neonatal severe morbidity

    Mechanical ventilation ≥ 48 hrs

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  11. Neonatal severe morbidity

    Severe bronchopulmonary dysplasia

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  12. Neonatal severe morbidity

    Severe intraventricular hemorrhage

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  13. Neonatal severe morbidity

    Cystic periventricular leucomalacia

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  14. Neonatal severe morbidity

    Early-onset sepsis

    Time frame: From birth to Day 3 after birth.

  15. Neonatal severe morbidity

    Necrotizing enterocolitis

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  16. Neonatal severe morbidity

    Retinopathy of prematurity

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  17. Neonatal morbidity

    Severe fetal acidemia

    Time frame: At birth.

  18. Neonatal morbidity

    Respiratory distress syndrome

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  19. Neonatal morbidity

    Mild or moderate bronchopulmonary dysplasia

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  20. Neonatal morbidity

    Grades I-II intraventricular hemorrhage

    Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.

  21. Neonatal morbidity

    Late-onset sepsis.

    Time frame: From Day 3 after birth to discharge from hospital, with a maximum of 24 weeks after birth.

  22. Vital status

    Death between discharge and follow up at 2 years

    Time frame: At 22-26 months of corrected age

  23. Frequency of Gross motor impairment among children alive at 2 years of corrected age

    Cerebral palsy

    Time frame: At 22-26 months of corrected age

  24. Frequency of Neurosensory impairment among children alive at 2 years of corrected age

    Visual impairment

    Time frame: At 22-26 months of corrected age

  25. Frequency of Neurosensory impairment among children alive at 2 years of corrected age

    Hearing impairment

    Time frame: At 22-26 months of corrected age

07

Study locations

1 site
08

References and documents

Publications

  • Mackeen AD, Seibel-Seamon J, Muhammad J, Baxter JK, Berghella V. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev. 2014 Feb 27;2014(2):CD007062. doi: 10.1002/14651858.CD007062.pub3. PubMed 24578236 ↗
  • Lorthe E, Goffinet F, Marret S, Vayssiere C, Flamant C, Quere M, Benhammou V, Ancel PY, Kayem G. Tocolysis after preterm premature rupture of membranes and neonatal outcome: a propensity-score analysis. Am J Obstet Gynecol. 2017 Aug;217(2):212.e1-212.e12. doi: 10.1016/j.ajog.2017.04.015. Epub 2017 Apr 13. PubMed 28412086 ↗
  • Couteau C, Haumonte JB, Bretelle F, Capelle M, D'Ercole C. [Management of preterm and prelabour rupture of membranes in France]. J Gynecol Obstet Biol Reprod (Paris). 2013 Feb;42(1):21-8. doi: 10.1016/j.jgyn.2012.10.008. Epub 2012 Nov 24. French. PubMed 23182704 ↗
  • Schmitz T, Sentilhes L, Lorthe E, Gallot D, Madar H, Doret-Dion M, Beucher G, Charlier C, Cazanave C, Delorme P, Garabedian C, Azria E, Tessier V, Senat MV, Kayem G. Preterm premature rupture of the membranes: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2019 May;236:1-6. doi: 10.1016/j.ejogrb.2019.02.021. Epub 2019 Mar 2. PubMed 30870741 ↗
  • Flenady V, Wojcieszek AM, Papatsonis DN, Stock OM, Murray L, Jardine LA, Carbonne B. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev. 2014 Jun 5;2014(6):CD002255. doi: 10.1002/14651858.CD002255.pub2. PubMed 24901312 ↗
  • Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2. PubMed 35947046 ↗
  • Lorthe E, Kayem G; TOCOPROM Study Group and the GROG (Groupe de Recherche en Obstetrique et Gynecologie). Tocolysis in the management of preterm prelabor rupture of membranes at 22-33 weeks of gestation: study protocol for a multicenter, double-blind, randomized controlled trial comparing nifedipine with placebo (TOCOPROM). BMC Pregnancy Childbirth. 2021 Sep 8;21(1):614. doi: 10.1186/s12884-021-04047-2. PubMed 34496799 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Nov 2026, 85 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2019
First posted
Jun 5, 2019
StartActual
Oct 7, 2019
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2031
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03976063
Collaborators
Institut National de la Santé Et de la Recherche Médicale, France, Ministry of Health, France, Groupe de Recherche en Obstétrique et Gynécologie, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jun 5, 2019
Start date
Oct 7, 2019
Primary completion
Nov 2026 (estimated)
Completion
Nov 2031 (estimated)
Last update
Apr 23, 2026

Study contacts

Gilles Kayem, MD, PhD
principal investigator · INSERM UMR 1153, Obstetrical, Perinatal and PEdiatric Epidemiology (EPOPé) Research Team, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), DHU Risks in Pregnancy, Paris Descartes University, Trousseau University Hospital
Elsa Lorthe, RM, PhD
study director · INSERM UMR 1153, Obstetrical, Perinatal and PEdiatric Epidemiology (EPOPé) Research Team, Center of Research in Epidemiology and Statistics Sorbonne Paris Cité (CRESS), DHU Risks in Pregnancy, Paris Descartes University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion